Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib pharmacokinetics study in children aged 1 to under 4 years with CML, Ph+ ALL, or other indicated hematologic disorders
NL-OMON34200Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and Hematopathy, sponsored by Novartis. Primary endpoints: Clearance over bioavailability (CL/F), Volume of distribution over bioavailability (V/F) and 4 more. Started Oct 2010; status: active, not recruiting.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)Hematopathy
Beyond the preview
Go deeper on NL-OMON34200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34200.